AbbVie Sees Unusually High Options Volume (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBVGet Rating) was the target of some unusual options trading on Tuesday. Stock investors purchased 33,415 call options on the company. This represents an increase of 54% compared to the average volume of 21,664 call options.

Hedge Funds Weigh In On AbbVie

Institutional investors have recently modified their holdings of the stock. ICW Investment Advisors LLC boosted its stake in shares of AbbVie by 0.3% in the 1st quarter. ICW Investment Advisors LLC now owns 23,418 shares of the company’s stock valued at $3,796,000 after purchasing an additional 65 shares during the last quarter. Wealth Architects LLC raised its position in shares of AbbVie by 1.5% in the 1st quarter. Wealth Architects LLC now owns 4,511 shares of the company’s stock valued at $731,000 after acquiring an additional 67 shares during the period. Nicolet Advisory Services LLC raised its position in shares of AbbVie by 1.4% in the 1st quarter. Nicolet Advisory Services LLC now owns 5,111 shares of the company’s stock valued at $894,000 after acquiring an additional 70 shares during the period. JNBA Financial Advisors raised its position in shares of AbbVie by 0.7% in the 2nd quarter. JNBA Financial Advisors now owns 10,204 shares of the company’s stock valued at $1,563,000 after acquiring an additional 71 shares during the period. Finally, Capasso Planning Partners LLC raised its position in shares of AbbVie by 2.2% in the 2nd quarter. Capasso Planning Partners LLC now owns 3,238 shares of the company’s stock valued at $496,000 after acquiring an additional 71 shares during the period. Hedge funds and other institutional investors own 68.25% of the company’s stock.

AbbVie Stock Down 0.3 %

Shares of NYSE ABBV opened at $159.39 on Thursday. The company has a current ratio of 0.93, a quick ratio of 0.83 and a debt-to-equity ratio of 3.77. The stock has a market capitalization of $281.88 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 4.42 and a beta of 0.69. The stock’s fifty day simple moving average is $145.57 and its two-hundred day simple moving average is $145.75. AbbVie has a 12-month low of $115.10 and a 12-month high of $175.91.

AbbVie (NYSE:ABBVGet Rating) last posted its quarterly earnings data on Friday, October 28th. The company reported $3.66 earnings per share for the quarter, topping analysts’ consensus estimates of $3.57 by $0.09. The firm had revenue of $14.81 billion during the quarter, compared to analysts’ expectations of $14.95 billion. AbbVie had a return on equity of 155.88% and a net margin of 23.19%. The business’s quarterly revenue was up 3.3% on a year-over-year basis. During the same quarter last year, the firm earned $3.33 EPS. As a group, analysts expect that AbbVie will post 14.01 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 15th. Investors of record on Friday, January 13th will be paid a $1.48 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.41. The ex-dividend date of this dividend is Thursday, January 12th. This represents a $5.92 dividend on an annualized basis and a yield of 3.71%. AbbVie’s dividend payout ratio (DPR) is 75.30%.

Analyst Ratings Changes

Several brokerages have recently weighed in on ABBV. Morgan Stanley reduced their price target on AbbVie from $185.00 to $178.00 and set an “overweight” rating on the stock in a report on Monday, October 31st. BMO Capital Markets reduced their price target on AbbVie from $170.00 to $169.00 and set an “outperform” rating on the stock in a report on Monday, October 31st. Argus reduced their price target on AbbVie from $165.00 to $155.00 and set a “buy” rating on the stock in a report on Wednesday, August 24th. UBS Group reduced their price target on AbbVie from $154.00 to $146.00 and set a “neutral” rating on the stock in a report on Monday, August 1st. Finally, Atlantic Securities dropped their price objective on AbbVie from $162.00 to $157.00 and set a “neutral” rating on the stock in a research note on Monday, October 31st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $157.32.

About AbbVie

(Get Rating)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Recommended Stories

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.